A randomized, double-blind, placebo controlled, two-way cross-over study to explore the effects of 7 days of dosing with SYN115 20 mg p.o. bid or 60 mg p.o. bid on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease

Trial Profile

A randomized, double-blind, placebo controlled, two-way cross-over study to explore the effects of 7 days of dosing with SYN115 20 mg p.o. bid or 60 mg p.o. bid on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Synosia Therapeutics
  • Most Recent Events

    • 13 Jun 2010 Perfusion MRI results presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 14 Apr 2010 Perfusion MRI results presented at the 62nd Annual Meeting of the American Academy of Neurology.
    • 14 Apr 2010 Results presented at 62nd Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top